Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
45 Results for "
ROS aggregation
" in MedChemExpress (MCE) Product Catalog:
Products (45)
45 Results for "ROS aggregation" in MCE Product Catalog:
Cat. No.: HY-131660
CAS No.: 52688-60-5
Research Areas:
MAO-B-IN-54 is a selective, reversible and competitiv monoamine oxidase B (MAOB) inhibitor with a human IC50 of 0.052 μM and a Ki of 0.028 μM. MAO-B-IN-54 shows weak activity MAOA. MAO-B-IN-54 occupies both the entrance and substrate cavity of MAOB, forming hydrophobic and hydrogen bonding interactions. MAO-B-IN-54 inhibits Aβ aggregation and ROS production. MAO-B-IN-54 can be used for the research of Alzheimer’s disease .
Cat. No.: HY-184817
CAS No.: 2883627-63-0
Research Areas:
α-Synuclein-IN-22 is an α-Synuclein inhibitor with an IC50 of 2.7 μM against human α-Syn. α-Synuclein-IN-22 exerts anti-aggregation effects by stabilizing the native conformation of α-Syn, inhibiting the formation of β-sheet aggregates and inclusion bodies, and dissociating mature fibrils into functional monomers. α-Synuclein-IN-22 scavenges ROS and shows low cytotoxicity. α-Synuclein-IN-22 can be used in research related to Parkinson's disease .
Cat. No.: HY-180114
Research Areas:
NSS-18 is a potent and reversible inhibitor of AChE and MAO-B, with IC50 values of 1.53 and 1.51 μM respectively. NSS-18 can inhibit the self-aggregation of Aβ. NSS-18 inhibits the intracellular generation of ROS induced by Aβ. NSS-18 shows a moderate neuroprotective effect against 6-OHDA (HY-B1081)-induced neurotoxicity. NSS-18 can form chelates with metal ions such as Cu²⁺, Fe³⁺, and Zn²⁺, with the strongest chelation being with Cu²⁺. NSS-18 can be used for the study of Alzheimer's disease .
Cat. No.: HY-184815
CAS No.: 2883627-67-4
Research Areas:
α-Synuclein-IN-20 is an inhibitor of α-synuclein (α-Synuclein) with an IC50 of 4.1 μM against human α-Syn. α-Synuclein-IN-20 exerts anti-aggregation effects by stabilizing the native conformation of α-Syn, inhibiting the formation of β-sheet aggregates and inclusion bodies, and dissociating mature fibrils into functional monomers. α-Synuclein-IN-20 scavenges ROS, protects and repairs dopaminergic neurons, ameliorates Parkinson's disease-like symptoms, and shows low cytotoxicity. α-Synuclein-IN-20 can be used for research related to Parkinson's disease .
Cat. No.: HY-184818
CAS No.: 2883627-62-9
Research Areas:
α-Synuclein-IN-23 is an inhibitor of α-synuclein with an IC50 of 2.1 μM. α-Synuclein-IN-23 dissociates preformed α-synuclein aggregates, scavenges reactive oxygen species (ROS), and inhibits the formation of α-synuclein inclusions in neuronal cells. α-Synuclein-IN-23 can be used for the research of Parkinson's disease .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
